Debatforum

Eller skal man glemme alt om salg og genkøb. De kan sikkert blive endnu dyrere end nuværende. Hvad hvis forward p/e når 40?

Better safe than worry. Sådan indleder Helge Larsen investorernes reaktion på centralbankernes udmeldinger. Han samler desuden op på debatten om Zealand Pharma og Genmab og kommer ind på de nye chats, der er oprettet på ProInvestor.com. Ugekommentar #23 med redaktør på ProInvestor.com Helge Larsen. Om tendenser og aktier, som debatteres på ProInvestor.com. https://www.youtube.com/watch?v=ylLjSFFh1gk&t=1s

Der er nu knap 8746 forskellige crypto valutaer tilsalg. Heraf ved vi af mange løbende udstedes i større og større tal. Øhh .. undskyld. Det tal var fra i onsdags. Dagens tal er 9052. https://www.investing.com/crypto/currencies Det kommer til at gøre ondt ..... uff ! År 2022 .. det år hvor kryptovalutaerne forvandlede sig til den afklædte kejser og forvandlede 2 trilliarder Dollars til ??? mvh

I dagens afsnit 96 af Investeringspodcastenser Per Hansen og Helge Larsen på, om hvorvidt Robin Hood Markets og meme investering forbliver et 2021 fænomen. De tager bl.a. også et kig på et marked som, under overfladen, har fået kursprygl, og hvor julefreden bestemt ikke har sænket sig. https://www.nordnet.dk/blog/afsnit-96-af-investeringspodcasten-juleufreden-rammer-markedet/

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Company announcement - No. 76 / 2021 Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Interim analysis for the trial expected in third quarter of 2022 Copenhagen, DK and Boston, MA, U.S. December 16, 2021 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has enrolled the last patient required for the planned interim analysis of its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide the company's long-acting GLP-2 analog, under evaluation for the potential treatment of short bowel syndrome (SBS). "We are delighted to reach this important milestone in the glepaglutide Phase 3 trial, which is the result of diligent work by our clinical research team and trial investigators, who have all labored to minimize the impact of Covid-19 on recruitment," said Adam Steensberg, Chief Medical Officer at Zealand Pharma. "We have experienced tremendous support and commitment from, and are incredibly grateful to, all of the patients, doctors, nurses, dieticians and other hospital staff involved in conducting this trial, in our joint efforts to develop a novel and convenient treatment option for patients with short bowel syndrome." The planned interim analysis, expected in Q3 2022, is a result of ongoing dialogue with the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and will be conducted by an external independent Data Monitoring Committee (DMC), which will provide a recommendation to Zealand based on unblinded data. If the interim results are positive and allow for early stopping, Zealand plans to pursue a regulatory submission based on these data. The trial will remain blinded to the Company, trial investigators, and patients, to preserve the integrity of the trial. Zealand cannot disclose further details regarding the interim analysis during the remaining course of the trial. # About Short Bowel Syndrome (SBS) SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment. About Glepaglutide Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. The pivotal trial Phase 3 trial, EASE-SBS 1, with planned enrolment of up to 129 patients with SBS, is a randomized, double-blind and placebo-controlled study, with both once- and twice-weekly dosing regimens. The primary endpoint in EASE-SBS 1 is the absolute reduction in parenteral support achieved by the end of the trial. Patients will be treated for six months in EASE-SBS 1, whereafter they are offered four years continuous follow-up treatment with glepaglutide in the extension trials, EASE-SBS 2 and 3. A Phase 3b trial, EASE-SBS 4, was initiated in Q3 2021 and will assess long-term effects of glepaglutide on intestinal fluid and energy uptake.The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand's business and activities, please visit http://www.zealandpharma.com. Forward-Looking Statement This press release contains "forward-looking statements", as that terms is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products. These forward-looking statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. For further information, please contact: Zealand Pharma Investor Relations Maeve Conneighton Argot Partners [email protected] Zealand Pharma Media Relations David Rosen Argot Partners [email protected]

Kommentar fra Per Hansen, Investeringsøkonom, Nordnet Efter sidste uges store aktieudsalg er investorerne igen faldet til ro. De satser og indstiller sig på, at Omikron bliver enden på og ikke eskaleringen af Covid-krisen: · Omikron er aktuelt "navnet" på Covid · Det er ikke det første, men måske er det det sidste · Omkron smitter hurtigere end de tidligere · Til gengæld, siger de første data som investorerne køber ind på, er symptomerne med Omikron ikke så alvorlige som med de foregående · Det er absolut ikke ligegyldigt at/hvis det forholder sig sådan. · Eksplosiv smitte, men med færre symptomer er "the short term pain for the long term gain, hvis tesen viser sig at holde · Flere bliver smittede hurtigt, men flere smittede med mildere symptomer i givet fald, vil fremkalde den folkeimmunitet, som er begyndelsen på enden for Covid Stigende renter bliver 2022 udfordring og mulighed Her og nu er det Omikron, som de fleste bekymrer sig om. Det mest sandsynlige scenarie, her og nu, er at investorerne i starten af det nye år, vil fokusere langt mere på FEDs tapering og risikoen for 2 eller flere renteforhøjelser i 2022. Det vil give yderligere USD stigninger, stigende markedsrenter, udfordringer for vækstaktier, kan være enden på opturen for kurseksploderende vaccineaktier som Moderne og Biontech og give comeback til cykliske aktier med en lav prisfastsættelse. Omikron kan både bringe gode og dårlige nyheder. Under alle omstændigheder giver det formentlig et aktiemarked med lavere afkast, men ikke nødvendigvis med meget dårlige afkast, men det kræver en porteføljejustering.

Kommentar fra Per Hansen, Investeringsøkonom, Nordnet Den amerikanske centralbank, Federal Reserve fastholdt som ventet renten, vil lave hurtigere "tapering" og formentlig hæve renten 3 gange i 2022. Alligevel steg aktierne markant. Forvirret? · De seneste uger har FED løbende ændret sin rentepolitik · Fra at ville være tilbageholdende med en stramning af pengepolitikken, har FED chef Jerome Powell og andre signaleret, at det var tid til at pensionere udtrykket "midlertidig" i forbindelse med inflation og lade pengepolitikken følge inflationen (op) · FED fastholdt som forventet på kort sigt sin rente · FED vil accelerere udfasningen af deres obligationsopkøb hurtigere · Og ser en inflation på 2,6-2,7 % i 2022 · Samtidig viser deres "rentedots", at de formentlig vil hæve renten 3 gange i 2022 · Umiddelbart steg aktier; derefter faldt de tilbage igen for at sluttede markant højere på dagens højeste niveau. · USD steg initielt, men endte dagen i et lille netto fald Forståelig forvirring over stor aktiestigning Hvis investorerne er forvirrede er det helt naturligt og forståeligt. FED ER blevet mere høgeagtig, men rygterne om at rentehøgen kommer er/var fløjet så meget i forvejen, at investorerne på kort sigt, trods alt, ikke blev meget overraskede. Inflationsforventningerne for 2022 blev ikke justeret meget, og reelt er der under overfladen ikke ekstra "her og nu" rentesprængstof, som kan gøre investorerne meget mere bange kortsigtet. Samtidig er "rentedots" behæftet med meget stor usikkerhed og skal altid følges op af et "alt andet lige". Uanset, er den markante aktiestigning alligevel lidt af en overraskelse, men den går, givet at renterne ikke bevægede sig, samtidig hånd i hånd med en moderat USD svækkelse/dans på stedet. Hvis ECB og Christine Lagarde fastholder sin mere dueagtige pengepolitik i forbindelse med dagens møde og efterfølgende pressekonference, er der gode muligheder for at USD kan stige yderligere i 1. kvartal 2022. Det vil være gode nyheder for dansk økonomi og ikke mindst for eksportorienterede selskaber som Lundbeck, Novozymes, Novo Nordisk, Demant, m.fl.

The DuoBody technology platform is the basis of many BispecificAntibodies in our pipeline. Learn more about the background of this platform in this podcast episode https://vimeo.com/636105275/ba065aeec3

Rammeaftale med Health-Tech gigant sikrer pipeline med "tocifret" millionomsætning 10.12.2021 10:00 CET ' Scandinavian Medical Solutions A/S ' Investor Nyheder Investornyhed Nr. 4 Scandinavian Medical Solutions (eller 'Selskabet') har netop vundet et historisk stort udbud på 13 brugte MRI- scannere via Siemens Healthineers. Nu skal den nordjyske handelsvirksomhed demontere de dyrebare scannere og distribuere dem globalt med et fast mål om at øge scanningskapaciteten overalt. Scandinavian Medical Solutions har vundet en historisk stor ordre i branchen for handel med brugt medicinsk udstyr. Normalt hyrer den vindende producent flere leverandører til at løse opgaven med at demontere, flytte og videredistribuere det højteknologiske udstyr. Men i forbindelse med det te store EU-udbud skal Scandinavian Medical Solutions altså være den eneste underleverandør til demontering og videresalg af samtlige 13 MRI - scannere. "Nu kan vi sørge for, at de livreddende maskiner i Region Hovedstaden ikke går tabt, men bliver leveret til hospitaler, der har behov for øget scanningskapacitet i resten af verden. Vi har allerede nu etableret salgskanaler på en fjerdedel af scannerne," siger CEO Jens Krohn, At demontere og flytte en MRI -scanner er ingen let sag at løse. Den indlejrede heliumteknologi i MRI -scannere anses i sig selv for at være en raketvidenskab at flytte rundt på. Dog er der ingen brist i tilliden til Scandinavian Medical Solutions, der nu har det fulde ansvar for højkvalitetsscannerne til hospitaler, der har behov for øget scanningskapacitet. "Vi dobbelttjekker altid alt udstyr og løber en ekstra mil for at sikre kvaliteten. En MRI -scanner kræver samme service som en flymotor, hvor der er fuld gennemsigtighed om tilstanden på alle komponenterne i maskinen. Nu kan vi se, at vores grundige arbejde giver pote hos de helt store aktører på markedet. Den ekstraordinære ordre fra Siemens Healthineers er en solid blåstempling af vores løsning, og det er en meget validerende tillidserklæring, når virksomheder i verdensklasse vil handle med os igen og igen," fortæller CEO Jens Krohn. De 13 MRI-scannere er alle placeret på hospitaler i Region Hovedstaden og bliver løbende demonteret fra nu af og frem mod begyndelsen af 2023. Brugt medicinsk udstyr fra den nordlige del af Europa er i høj kurs, fordi udstyret som regel er velserviceret. "Vi er stolte af allerede nu påbegynde et arbejde, som forstærker vores markedsposition og sikrer en yderligere tocifret millionomsætning frem mod 2023. Vi arbejder hver dag på at vinde flere udbud af samme kvalitet for at understøtte fremtidig vækst til gavn for investorer og det internationale behov for scanningskapacitet," siger CEO Jens Krohn. Scandinavian Medical Solutions fortsætter med at have fokus på at accelerere kerneforretningen yderligere ved kontinuerligt at arbejde på at tilbyde en bredere produktportefølje. Sådan kan Selskabet imødekomme kunders behov og efterspørgsel på højkvalitets scanningsudstyr og navigere bedst muligt i en ofte volatil global økonomi. Ordren ændrer på nuværende tidspunkt ikke forventninger til regnskabsåret 2021/22, men bidrager til en stabilitet i omsætningen frem mod 2023, hvor de sidste af de 13 MRI-scannere demonteres. Supplerende Information For spørgsmål vedrørende denne selskabsmeddelelse kan Selskabets CEO, Jens Krohn, kontaktes på [email protected]. Selskabets Certified Adviser er Norden CEF A/S, hvor John Norden kan kontaktes via e-mail på [email protected] eller telefonisk på +45 2072 0200. Scandinavian Medical Solutions A/S Gasværksvej 46,1., DK - 9000 Aalborg CVR-nummer: 39901749 Scandinavien Medical Solution har en betalt digital IR-aftale med Proinvestor.com

15 Dec 2021 06:00 First North-noterede Trophy Games opkøber det canadiske spilstudie, Tiny Titan Studio der blandt andet står bag den populære titel Tiny Rails. Trophy Games, der d. 27. april blev børsnotereret på Nasdaq First North, har foretaget deres andet opkøb efter de har annonceret opkøbet af det canadiske spilstudie Tiny Titan Studio. Tiny Titan Studio står bag flere populære spil i arcade genren, hvor det mest populære er titlen Tiny Rails. Selskabet blev stiftet i 2014 i Ontario i Canada og har siden da udgivet 10 kritikerroste spiltitler, der over årene har fået mere end 25 millioner downloads på verdensplan. Trophy Games opkøber 100% af Tiny Titan Studios, eksklusiv deres PC portefølje og medarbejdere, og betaler hele handlen kontant. Trophy Games' CEO, Søren Gleie, udtaler om offentliggørelsen: "Vi er utroligt glade for, at det er lykkedes os at lukke handlen med Tiny Titan. De har bygget en stærk portefølje af populære spil i arcade-genren, der har fået 796.757 organiske downloads de seneste tre måneder på Google Play alene og samtidig har et positivt cash flow. Tiny Titan forventes at generere en omsætning på DKK 2,8m i kalenderåret 2021. Vi tror, vi kan forbedre monetisation af spillene og gøre god brug af deres assets. Det kan være med til at skabe en stærk indtægtsstrøm i mange år fremad for Trophy Games - og være endnu en god langtids-spiloplevelse for vores brugere oveni vores egen nuværende portefølje af spil. Med opkøbet af Tiny Titan Studio fortsætter Trophy Games deres ambitiøse vækstplan fra børsnoteringen, hvor 40% af de rejste penge efter planen skulle gå til at vækste selskabet gennem konsoliderende opkøb. Søren Gleie udtaler desuden: "Vi har haft enorm succes med vores første opkøb af Xombat, så det er fedt at anden handel nu er kommet i hus. Vi forventer, at der følger flere opkøb over det kommende år, så vi kan bygge oven på hvad der allerede er en solid forretning med 15 års vækst i træk." Kontaktinformation Søren Gleie, CEO i Trophy Games - Email: [email protected] Trophy Games har betalt digital IR-aftale med Proinvestor.com [image: 99449_TinyRails_screenshot.png]

Her er 5 bud fra Matthew Frankel fra The Motley Fool. https://www.proinvestor.com/investornyt/744980/5-bold-predictions-for-the-stock-market-in-2022 Jeg er enig i bud nr. 1, 2 og 5. De to sidste (3 og 4) har jeg ikke nogen kvalificeret mening om. Hvad er dine bud på aktiemarkedet 2022?

Da omikron blev kendt tog markedet en hurtig lille nedtur. I sidste uge rejste kursen sig igen i en lille "bulltrend" men lavede vidst ikke ny top. Men idag fiser den ned igen og daily-kortet er måske pænt købt. Kunne markedet tage sig en større dukkert igen her i denne uge? Shorterne har måske overtaget overfor nogle for optimistiske investorer?

Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Company announcement - No. 75 / 2021 Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note The non-dilutive debt facility will support continued development of clinical pipeline, including additional indications for dasiglucagon and glepaglutide, as well as earlier stage pipeline investigating unmet needs in obesity and inflammatory diseases Copenhagen, DK and Boston, MA, U.S. December 14, 2021 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced a financing agreement with Oberland Capital Management LLC ("Oberland Capital"). The agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note (the "Secured Note"). In addition to the $100 million upfront payment, Zealand will receive the following: $50 million in exchange for an additional note with terms and conditions consistent with the Secured Note, available at Zealand's option any time prior December 31, 2023, following receipt of approval of glepaglutide for the treatment of short bowel syndrome (SBS) by the Food and Drug Administration; Up to $50 million in exchange for an additional note on terms to be mutually agreed upon, available at Zealand's option any time prior to June 30, 2023, to acquire products and/or companies; The interest rate for the Secured Note is 6.0% plus 3-month LIBOR or 0.25%, whichever is greater Oberland Capital will also receive a low single-digit royalty obligation on net sales during the term of the agreement. "This new funding from Oberland Capital enables us to continue to selectively invest in our robust clinical-stage pipeline, which includes multiple programs in Phase 3 trials across a range of metabolic and gastrointestinal diseases, as well as in our pre-clinical pipeline," said Matthew Dallas, Senior Vice President and Chief Financial Officer at Zealand Pharma. "Importantly, in addition to the initial $100 million upfront payment, a further $50 million becomes available on the potential approval of glepaglutide for the treatment of SBS, where we anticipate Phase 3 pivotal trial results in Q3 of 2022." "We are delighted to support Zealand in its mission to develop and commercialize medicines for patients in need of new treatments for metabolic and gastrointestinal diseases," said William Clifford, Partner at Oberland Capital. "The Zealand team has a clear mission of delivering five commercialized products by 2025, aiming to change the lives of patients, and we are excited to partner with them on this path forward." About Oberland Capital Oberland Capital, a private investment firm with over $2.25 billion in capital commitments since inception, is focused exclusively on investing in the global healthcare industry and specializes in flexible investment structures customized to meet the specific capital requirements and strategic objectives of its transaction partners. Oberland Capital's broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for its transaction partners. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand's business and activities, please visit http://www.zealandpharma.com. For further information, please contact: Zealand Pharma Investor Relations Maeve Conneighton Argot Partners [email protected] Zealand Pharma Media Relations David Rosen Argot Partners [email protected]

"Fortsatt uppåt för AO Sverige - tankar finns på fler etableringar Danska grossistkoncernen AO Johansens svenska dotterbolag AO Sverige AB visar en fortsatt ökad lönsamhet och tillväxt för 2020. Försäljningschef David Carlbom säger till Installationssiffror.se att ägaren vill utveckla verksamheten i Sverige, och att eventuella nya etableringar ses över." https://www.installationssiffror.se/ https://www.allabolag.se/5565863148/ao-sverige-ab https://aonet.se/hitta-oss https://www.vvsochbad.se/ PE (2021)=12-13 PE (2022)=9-10 (ifølge mig)

GN Hearing acquires New York based Lively - a leader in online hearing care 14.12.2021 • GN Hearing acquires New York based Lively - a leading online hearing care and digital marketing platform, enabling consumers to explore, purchase and receive hearing care from licensed hearing care professionals in the U.S. all from the comfort of their home • Following the acquisition, GN Hearing gains access to the fast-growing telehealth market, utilizing a proven business model with rapid growth • Today, two-thirds of Lively's consumer inquiries are looking for either an online experience with access to a clinic or have severe to profound losses requiring in-clinic care. When combining GN Hearing and Lively, a new offering will be developed to meet these consumers' needs by providing access to GN Hearing's network of hearing care professionals • The purchase price is DKK 625 million on a debt and cash free basis for 91% ownership of Lively Gitte Aabo, CEO of GN Hearing, says: "Today, only one in five people who could benefit from hearing improvement wears hearing aids. Hearing health is being elevated on the overall healthcare agenda. Lively and GN Hearing joining forces will combined with our network of hearing care professionals be an important part of bringing hearing health to a new level." Adam Karp, CEO of Lively, says: "We are thrilled to join the GN family due to the company's advanced tele-audiology solutions, pioneering spirit in connectivity and unique sound processing capabilities. In addition to our premier online experience using licensed hearing care professionals virtually, together with GN Hearing's network of Beltone and ReSound customers, we can develop new offerings for many more potential consumers who seek both an online experience and access to a clinic. Being part of GN will accelerate our growth and ability to achieve our vision to empower everyone to reach their full hearing potential." Lively Headquartered in New York City, U.S., Lively was founded in 2018 by Adam Karp, Elad Kolet and Nicole Cadoret and built on Redesign Health, a platform that powers innovation in healthcare. Lively's mission is to empower people with hearing loss to connect with their world through effortless technology and delightful care. Pioneering a fully virtual hearing care journey, Lively is a customer-first, end-to-end audiology platform that makes it easier for users to buy advanced hearing technology with licensed professional care. Lively has consistently delivered on high customer satisfaction with a Net Promoter Score above 60, while return rates have been significantly below comparable offerings in the market. As one of the most integrated digital marketing platforms in hearing health, Lively has deep expertise in engaging with customers that are active on social media and are becoming more and more comfortable buying online. These customers are almost ten years younger than users seen in hearing care clinics. GN Hearing has been the sole supplier of hearing aids to Lively since the company launched providing the opportunity to closely follow the success of Lively and interact with the management team. GN Hearing and Lively share the ambition of bringing hearing health to even more people. Lively offers GN Hearing's current hearing care professionals scale and a platform to operate, engage and compete online for these younger, more tech-savvy consumers who are looking for access to a physical clinic or seeking solutions for severe to profound hearing loss that cannot be served virtually. Today's online market is estimated to account for around 4% of the U.S. hearing care market. With the coming introduction of OTC devices and younger consumers seeking hearing solutions, the online segment is expected to grow at a much faster pace than other segments. Lively has executed strongly on its competitive advantages and has outgrown the market since inception. In 2021, Lively is expected to deliver revenue of around DKK 100 million and an EBITA of around DKK -170 million reflecting the early-stage growth profile of the company. Strategic rationale With the increasing digitalization of the world, consumers demand online solutions and services also from the hearing industry. The online space has been growing for several years and has been accelerated by the pandemic. Further, the U.S. OTC hearing aid regulation is expected to expand the market, in particular by driving earlier adoption for people with mild-to-moderate hearing loss and younger consumer segments. GN Hearing has prepared for the emergence of a future environment that now crystalizes. GN Hearing's strategy has centered on not owning retail locations that compete with our customers. The acquisition of Lively will directly benefit GN Hearing's network of hearing care professionals by adding valuable capabilities to GN's operations, including digital channel access, in-depth expertise of digital marketing and telehealth, and data driven consumer behavior to attract new, younger consumers. Key transaction highlights Following the transaction, GN Hearing has an ownership of 91%, while the remaining 9% is held by the current management team of Lively, with GN Hearing having an option to acquire the remaining 9% at pre-defined terms. The purchase price is DKK 625 million for the acquisition of Lively on a debt and cash free basis and the transaction is expected to close within a week when all relevant documents are in place. The transaction will be financed as 100% cash payment and GN's long-term leverage target of 1-2x NIBD/EBITDA is confirmed. The financial guidance for 2022, including Lively, will be communicated in connection with the Annual Report 2021. Læs mere: https://www.gn.com/Newsroom/News/2021/December/GN-Hearing-acquires-New-York-based-Lively

Dette er hovedsagelig ment til eventuelle nye her på siden, som måske ikke er opmærksom på skat, og de muligheder der er for at optimere. Her ved afslutningen af året bør man overveje den skattemæssige konsekvens af årets handler til nu. Har man realiseret en gevinst kan man vælge bare at betale regningen, som jo lander primo 2022. Man kan også overveje om man skal tage nogle tab, rydde ud i de aktier som man måske ikke længere mener har potentiale. Derved nedsætter man den udskudte skat, eller tager måske et tab med ind i det nye år til modregning i gevinster senere. Man skal selvfølgelig også medtage i sit regnestykke de ekstra omkostninger der følger med handler. Salg og køb er op til den enkelte, skal overvejes ud fra hvordan porteføljen ser ud, herunder værdi og risikoprofil. Der er mange parametre at medtage i sine overvejelser, og der er ingen skabelon der passer alle. Min egen strategi er altid at sælge de aktier som ikke længere har det potentiale den havde ved køb, eller hvor andre ting gør at den er uinteressant Jeg vil derfor tage udgangspunkt i et eksempel som vedrører min situation. Så kan man sammenligne med sin egen hvis man er interesseret. Hvis man har frie midler til at betale den regning der venter er der ingen ko på isen. Det mest optimale vil jo være at lade porteføljen vokse over tid (handle så lidt som muligt). Ved salg, når det er muligt, kun at sælge op til beløbet for den høje sats (p.t 55600). Min egen situation har i år har været speciel. Først skal det siges at jeg kun har 5 "sikre" aktier, resten er biotek. Derfor er jeg i den helt mørkerøde ende i.f.t risiko. Jeg har henover året realiseret en ret stor gevinst i mit Nordnet depot. Disse penge er flyttet til min bankforbindelse, idet vi skal bruge pengene i 2022. Desværre valgte jeg straks at placerer pengene i blandt andre Hansa og Quantafuel (for at undgå minusrenter). Disse har skuffet fælt, til nu. Jeg har derfor valgt at sælge igen, med et pænt tab. Dette dog efter grundige overvejelser. Hvis jeg ikke tog dette tab kunne jeg ende med at stå med BÅDE skatteregning, samt aktier i minus i det nye år. Jeg kunne også have valgt, til næste år, at sælge yderligere ud af mine aktier i plus. Det vil jeg imidlertid ikke, idet der for mange af dem forventes gode nyheder ultimo 2021, primo 2022. Som skrevet længere oppe, der er mange parametre at medtage i sine overvejelser. Det eneste man er sikker på er at skatteregningen kommer. Kendte man porteføljens værdi i fremtiden var det ikke så svært SMILEY. Det gælder altså om at gøre sine overvejelser nu, så man ikke bliver fanget på det forkerte ben i det nye år. Jeg har vedhæftet et Excelark jeg bruger til at lave scenarier i. Det er lidt simpelt, men virker. I kan jo selv forbedre hvis i synes. God weekend PS: Arket ser ikke ud til at komme med, trods en af de tilladte (Excel)

Hej Hvis man solgte sine tegningsretter i alm brand tidligere i forbindelse med pensionsdepot, tæller indtægten så med i årets skatteopgørelse (depotværdi vistnok pr. 15 jan 2022) som almindelige aktiehandeler / deportværdi der beskattes med PAL? I Nordnet er den en opfordring om at tjekke tegningsrethandlens beløb, men det ser vidst rigtigt ud hos mig. Alm brand og Lundbeck, er da de mest tåbelige selskaber jeg har haft aktier i, i klasse med Bioporto.

11.00 PM CET / 13-Dec-2021 / Cantargia AB (STO:CANTA) Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model Cantargia AB today reported new preclinical results demonstrating efficacy of the CAN10 antibody in a systemic sclerosis disease model where CAN10 counteracted disease development in the skin and lungs. Notably, the levels of several biomarkers affected in systemic sclerosis patients were normalized by CAN10 in this model. These results support clinical development of CAN10 in systemic sclerosis and results are planned to be presented at a scientific conference during Q1 2022. The CAN10 antibody binds interleukin-1 receptor accessory protein (IL1RAP) with high affinity and functions through simultaneous blockade of IL-1, IL-33 and IL-36 signaling. Development of CAN10 is initially planned to focus on two severe diseases: myocarditis and systemic sclerosis. Systemic sclerosis is a life-threatening autoimmune disease involving inflammation and subsequent fibrosis, i.e. uncontrolled scar tissue formation, in skin and internal organs. In an in vivo systemic sclerosis model, a surrogate CAN10 antibody reduced disease development in both skin and lungs. Further analyses of the skin also revealed that CAN10 normalized several biomarkers, i.e. gene signatures, which were dysregulated in skin biopsies from systemic sclerosis patients, suggesting that IL1RAP inhibition by CAN10 may lead to the same benefits in human disease as well. Together, these results support the clinical development of CAN10 as a new first-in-class treatment of systemic sclerosis and results are planned to be presented at a scientific conference during Q1 2022. "We are excited about these new results, showing strong effects of CAN10 in a systemic sclerosis model. Cantargia is committed to develop new therapies for life-threatening diseases and we look forward to advance this promising project to treatment of patients." said Göran Forsberg, CEO of Cantargia. The CAN10 antibody is in late-stage preclinical development. Cantargia plans to initiate a clinical phase I study for CAN10 in Q3 2022. For further information, please contact: Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: [email protected] Cantargia har betalt IR-aftale med Proinvestor.com

2cureX announced today it has reached its goals for the 2021 rollout plan with the signature of distribution agreements with two companies of the Diamedica OU Group, to promote and sell the IndiTreat tests in Latvia and Lithuania. 2cureX has signed two agreements with Diamedica Latvia and Diamedica Lithuania, making them distributors of IndiTreat products in their respective countries. The companies will promote IndiTreat to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen. The announcement follows previous statements by 2cureX about the European distributor network rollout (Q2 2021 Report). Believing in personalized cancer treatment "Diamedica Latvia is a leading and valued partner for all Oncology Hospitals in the country. Now, offering IndiTreat, we stay ahead in offering the most advanced tools to optimize cancer treatments" said Aksels Kaimins, Board member from Diamedica Latvia "At Diamedica Lithuania we firmly believe that every single mCRC patient should receive a personalized treatment to increase their life expectancy, therefore we are glad to introduce IndiTreat in our country" stated Stasys Krizanauskas, General Director of Diamedica Lithuania. The Baltics - small but important markets "Through our cooperation with Diamedica we get fast access to important decision makers in the Baltics. There is a close relation between the Baltic countries and Denmark, and we are glad to offer to patients and oncologists in these two countries the benefits of the information provided by the IndiTreat test" said Jesper Floyd Kristiansen, VP Business Development at 2cureX. Plan completed "We welcome Diamedica Latvia and Lithuania to the 2cureX family and are glad to see they share our excitement about IndiTreat. With these two agreements, we have secured distribution of IndiTreat in 11 countries, covering more than 20% of the European population. We have therefore reached the ambitious goals for the 2021 rollout plan described in the Q2 report, and we stand on the threshold of a very exciting 2022 thanks to our strengthened commercial organization", said Fernando Andreu, CEO of 2cureX. The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022. For more information about 2cureX: Fernando Andreu, Chief Executive Officer E-mail: [email protected] Telephone: +45 2279 5399 www.2curex.com 2cureX har en betalt digital IR-aftale med Proinvestor.com [image: 99402_120657426_10225204010113205_6858364698840976241_n.jpg]

Det er lidt svært for de små selskaber på FirstNorth at trænge igennem med nyheder, der skaber mere viden og tillid til deres vækst. De større finansmedier beretter om ordrer og nye tiltag i disse selskaber, men så er det jo godt, at vi har ProInvestor og vores debat-forum til at fortælle om de selskaber, som vi har investeret i, og som vi synes fortjener, at få udbredt deres positive nyheder. FOM Technologies har nemlig i to omgange - 6/12 og 9/12 - på deres investor-site meddelt, dels at de er blevet optaget som medlem af et førende amerikansk konsortium for forskning i solenergi, kaldet US-MAP. CEO i FOM udtalte i den anledning: "Det er helt unikt, at vi som lille dansk teknoloigvirksomhed nu sidder med om bordet, og har indvirkning på den strategiske retning af solenergiforskning i USA." Og den 9/12 meddelte FOM, at print- og kopigiganten Xerox Holding Corp. tildelte FOM en kontrakt på slot-die coating udstyr. I den anledning udtalte CEO:" Det er en kæmpe anerkendelse at skulle levere udstyr til en virksomhed som Xerox, opfinderen af både laserprinteren og fotokopieringsmaskinen, og i en vis henseende den første Apple PC..." I begge meddelelser fortæller FOM, at nyhederne ikke ændrer ved den økonomiske guidance for 2021. Til gengæld vurderer jeg, at vi her har at gøre med et spændende selskab, der med stor sandsynlighed vil blive ved med at tiltrække store ordrer fra anerkendte aktører. Her kommer link til børsmeddelelserne: https://www.fomtechnologies.com/investor/announcements-and-reports